Health Care Resource Utilization (HCRU) and Cost of Management of Cytokine Release Syndrome (CRS) and Neurological Events (NEs) in Patients with R/R Follicular Lymphoma (FL) Receiving Lisocabtagene Maraleucel (liso-cel) in the TRANSCEND FL Study

被引：0
|
作者：
Saunders, Ashley C. [1 ]
Singh, Tavneet [2 ]
Lee, Abraham [2 ]
Farazi, Thalia [3 ]
Fasan, Omotayo [1 ]
Mirza, Sana [2 ]
McGarvey, November [2 ]
机构：
[1] Bristol Myers Squibb, Princeton, NJ USA
[2] BluePath Solut, Los Angeles, CA USA
[3] Bristol Myers Squibb, San Francisco, CA USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-178771
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 24 条
  • [21] Lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (pt) with R/R large B-cell lymphoma (LBCL): 3-year follow-up (FU) from the randomized, phase 3 TRANSFORM study
    Kamdar, Manali Kirtikumar
    Solomon, Scott R.
    Arnason, Jon
    Johnston, Patrick B.
    Glass, Bertram
    Bachanova, Veronika
    Ibrahimi, Sami
    Mielke, Stephan
    Mutsaers, Pim
    Hernandez-Ilizaliturri, Francisco J.
    Izutsu, Koji
    Morschhauser, Franck
    Lunning, Matthew Alexander
    Chow, Victor A.
    Santamaria, Josu
    Colicino, Silvia
    Ogasawara, Ken
    Stepan, Lara
    Abramson, Jeremy S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [22] Improved Quality of Life (QOL) with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Compared with Standard of Care (SOC) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 3 Transform Study
    Abramson, Jeremy S.
    Solomon, Scott R.
    Arnason, Jon E.
    Johnston, Patrick B.
    Glass, Bertram
    Crotta, Alessandro
    Montheard, Sandrine
    Previtali, Alessandro
    Liu, Fei Fei
    Braverman, Julia
    Guo, Shien
    Shi, Ling
    Kamdar, Manali
    BLOOD, 2021, 138 : 3845 - +
  • [23] Phase 3 TRANSFORM study of lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor T cell therapy (Tx), versus standard of care (SOC) of salvage chemotherapy followed by autologous stem cell transplantation (ASCT) as second-line (2L) Tx in patients (pt) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL)
    Glass, Bertram
    Kamdar, Manali
    Solomon, Scott
    Arnason, Jon
    Johnston, Patrick B.
    Ibrahimi, Sami
    Mielke, Stephan
    Mutsaers, Pim
    Hernandez-Ilizaliturri, Francisco
    Izutsu, Koji
    Morschhauser, Franck
    Lunning, Matthew
    Maloney, David
    Crotta, Alessandro
    Montheard, Sandrine
    Previtali, Alessandro
    Stepan, Lara
    Ogasawara, Ken
    Abramson, Jeremy
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 165 - 166
  • [24] Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients ( Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study
    Kamdar, Manali
    Solomon, Scott R.
    Arnason, Jon E.
    Johnston, Patrick B.
    Glass, Bertram
    Bachanova, Veronika
    Ibrahimi, Sami
    Mielke, Stephan
    Mutsaers, Pim G. N. J.
    Hernandez-Ilizaliturri, Francisco J.
    Izutsu, Koji
    Morschhauser, Franck
    Lunning, Matthew A.
    Maloney, David G.
    Crotta, Alessandro
    Montheard, Sandrine
    Previtali, Alessandro
    Stepan, Lara
    Ogasawara, Ken
    Mack, Timothy
    Abramson, Jeremy S.
    BLOOD, 2021, 138
123